

# POLYPEPTIDE GROUP AG CHF0.01

ISIN: CH1110760852 WKN: 111076085 Asset Class: Stock

<b>Company</b>	2024/07/31 17:31:39
<b>Price</b>	<b>29.40</b>
	CHF
<b>Difference</b>	<b>-0.17% (-0.05)</b>



<b>Contact Details</b>	
POLYPEPTIDE GROUP AG	Tel: +41-43-502-05-80
--	Fax: +
Neuhofstrasse 24	Web: <a href="http://www.polypeptide.com">http://www.polypeptide.com</a>
6340 Baar	E-mail: <a href="mailto:info@polypeptide.com">info@polypeptide.com</a>

## Company Profile

PolyPeptide Group AG engages in the business of development, manufacturing, and marketing of peptide- and oligonucleotide-based compounds for use in the pharmaceutical and related research industries. It operates through the following business areas: Custom Projects, Contract Manufacturing, and Generics and Cosmetics. The Custom Projects business area includes manufacturing of custom research-grade peptides and oligonucleotides for use in pre-clinical and clinical development as well as for regulatory and scientific studies. The Contract Manufacturing business area focuses on peptides for commercial stage peptide therapeutics, at scale, in commercial batches and in accordance with current Good Manufacturing Practice (cGMP) requirements. The Generics and Cosmetics business area is involved in peptide-based generics for the human and veterinary market, produced on an industrial scale following cGMP guidelines. The company was founded in 1996 and is headquartered in Zug, Switzerland.

## Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
<b>Current assets</b>	303,651,000		248,405,000		343,596,000	
<b>Common stock capital</b>		280,000		298,000		312,000
<b>Fixed assets</b>	337,013,000		320,133,000		272,957,000	
<b>Equity capital of a company</b>		354,435,000		416,372,000		436,402,000
<b>Cash and cash equivalents</b>	88,980,000		37,055,000		141,231,000	
<b>Accrued liabilities</b>		24,879,000		28,746,000		45,123,000
<b>Other assets</b>	-		-		-	
<b>Current liabilities</b>		164,050,000		94,843,000		107,720,000
<b>Prepayments and accrued income</b>	-		-		-	
<b>Non-current liabilities</b>		122,178,000		57,322,000		72,431,000
<b>Different income</b>		-		-		-
<b>Other liabilities</b>		30,730,000		9,291,000		10,674,000
<b>Total assets</b>	640,664,000	640,664,000	568,538,000	568,538,000	616,554,000	616,554,000

## Balance notes

	2023	2022	2021
<b>Accounting standard</b>	IFRS	IFRS	IFRS
<b>Employees</b>	1,273	1,219	1,101
<b>Equity ratio</b>	55.32%	73.24%	70.78%
<b>Debt-equity ratio</b>	80.76%	36.55%	41.28%

## Others

	2023	2022	2021
<b>Tax Expense Rate</b>	11.68%	-2.64%	21.04%

# POLYPEPTIDE GROUP AG CHF0.01

ISIN: CH1110760852 WKN: 111076085 Asset Class: Stock

## Income statement

	2023	2022	2021
<b>Turnover</b>	311,256,000	282,031,000	304,878,000
<b>Net income</b>	-49,976,000	7,796,000	51,069,000
<b>EBIT</b>	-51,532,965	11,481,848	70,862,264
<b>Operating income before taxes</b>	-56,585,000	7,595,000	64,674,000
<b>Cash Flow</b>	35,446,000	5,480,000	61,977,000
<b>Net interest income</b>	-7,120,000	-3,425,000	-3,344,000
<b>Research and development expenses</b>	1,423,000	1,247,000	1,520,000
<b>Income taxes</b>	-6,609,000	-200,000	13,605,000
<b>Result from investments in subsidiaries, associates and other</b>	0	0	0
<b>Revenues per employee</b>	254,726	241,034	288,485

## Board of Directors

Beat In-Albon	Member of the administrative board
Jane Salik	Member of the administrative board
Patrick Aebischer	Member of the administrative board
Philippe Weber	Member of the administrative board
Erik Schropp	Member of the administrative board
Peter Wilden	Chairman of the administrative board

## Members of Management Board

Juan-José Gonzalez	Chairman of Managing Board
Christina del Vecchio	Member of Executive Committee
Jens Fricke	Member of Executive Committee
Marc Augustin	Member of Executive Committee
Neil Thompson	Member of Executive Committee